- Home
- RMTI vs IFRX Comparison
RMTI vs IFRX Comparison
Compare RMTI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMTI
- IFRX
- Stock Information
- Founded
- RMTI 1994
- IFRX 2007
- Country
- RMTI United States
- IFRX Germany
- Employees
- RMTI N/A
- IFRX N/A
- Industry
- RMTI Biotechnology: Pharmaceutical Preparations
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- RMTI Health Care
- IFRX Health Care
- Exchange
- RMTI Nasdaq
- IFRX Nasdaq
- Market Cap
- RMTI 58.9M
- IFRX 53.5M
- IPO Year
- RMTI 1998
- IFRX 2017
- Fundamental
- Price
- RMTI $1.65
- IFRX $1.25
- Analyst Decision
- RMTI Strong Buy
- IFRX Strong Buy
- Analyst Count
- RMTI 2
- IFRX 5
- Target Price
- RMTI $4.00
- IFRX $7.40
- AVG Volume (30 Days)
- RMTI 3.0M
- IFRX 963.7K
- Earning Date
- RMTI 11-11-2025
- IFRX 11-07-2025
- Dividend Yield
- RMTI N/A
- IFRX N/A
- EPS Growth
- RMTI N/A
- IFRX N/A
- EPS
- RMTI N/A
- IFRX N/A
- Revenue
- RMTI $87,966,000.00
- IFRX $191,224.00
- Revenue This Year
- RMTI N/A
- IFRX N/A
- Revenue Next Year
- RMTI $10.99
- IFRX $1,216.24
- P/E Ratio
- RMTI N/A
- IFRX N/A
- Revenue Growth
- RMTI N/A
- IFRX 54.36
- 52 Week Low
- RMTI $0.78
- IFRX $0.71
- 52 Week High
- RMTI $5.15
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- RMTI 59.87
- IFRX 50.32
- Support Level
- RMTI $1.60
- IFRX $1.21
- Resistance Level
- RMTI $1.85
- IFRX $1.77
- Average True Range (ATR)
- RMTI 0.21
- IFRX 0.19
- MACD
- RMTI -0.01
- IFRX -0.02
- Stochastic Oscillator
- RMTI 50.55
- IFRX 37.57
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.